Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free MTD Stock Alerts

Mettler-Toledo International (MTD) Competitors

Mettler-Toledo International logo
$1,344.87 -0.39 (-0.03%)
As of 09/4/2026 03:58 PM Eastern
Compare

MTD vs. BRKR, RGEN, TECH, A, and BIO

Should you buy Mettler-Toledo International stock or one of its competitors? Mettler-Toledo International's main competitors and comparable companies include Bruker (BRKR), Repligen (RGEN), Bio-Techne (TECH), Agilent Technologies (A), and Bio-Rad Laboratories (BIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Mettler-Toledo International compare to Bruker?

Bruker (NASDAQ:BRKR) and Mettler-Toledo International (NYSE:MTD) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

79.5% of Bruker shares are held by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are held by institutional investors. 27.2% of Bruker shares are held by insiders. Comparatively, 0.7% of Mettler-Toledo International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bruker currently has a consensus target price of $56.64, suggesting a potential downside of 3.17%. Mettler-Toledo International has a consensus target price of $1,445.31, suggesting a potential upside of 7.47%. Given Mettler-Toledo International's higher probable upside, analysts plainly believe Mettler-Toledo International is more favorable than Bruker.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bruker
2 Sell rating(s)
5 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.43
Mettler-Toledo International
1 Sell rating(s)
8 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.33

Mettler-Toledo International has a net margin of 21.91% compared to Bruker's net margin of -2.35%. Bruker's return on equity of 12.47% beat Mettler-Toledo International's return on equity.

Company Net Margins Return on Equity Return on Assets
Bruker-2.35% 12.47% 4.91%
Mettler-Toledo International 21.91%-1,212.14%25.11%

Bruker has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market.

In the previous week, Mettler-Toledo International had 14 more articles in the media than Bruker. MarketBeat recorded 24 mentions for Mettler-Toledo International and 10 mentions for Bruker. Mettler-Toledo International's average media sentiment score of 1.08 beat Bruker's score of 0.64 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bruker
5 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mettler-Toledo International
14 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mettler-Toledo International has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bruker$3.50B2.55-$8.60M-$0.70N/A
Mettler-Toledo International$4.03B6.69$869.19M$44.4330.27

Summary

Mettler-Toledo International beats Bruker on 11 of the 16 factors compared between the two stocks.

How does Mettler-Toledo International compare to Repligen?

Mettler-Toledo International (NYSE:MTD) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Mettler-Toledo International has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, Repligen has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Mettler-Toledo International presently has a consensus target price of $1,445.31, indicating a potential upside of 7.47%. Repligen has a consensus target price of $166.43, indicating a potential downside of 0.70%. Given Mettler-Toledo International's higher possible upside, analysts plainly believe Mettler-Toledo International is more favorable than Repligen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mettler-Toledo International
1 Sell rating(s)
8 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.33
Repligen
0 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
3 Strong Buy rating(s)
3.00

Mettler-Toledo International has a net margin of 21.91% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Mettler-Toledo International's return on equity.

Company Net Margins Return on Equity Return on Assets
Mettler-Toledo International21.91% -1,212.14% 25.11%
Repligen 5.29%5.30%3.79%

In the previous week, Mettler-Toledo International had 12 more articles in the media than Repligen. MarketBeat recorded 24 mentions for Mettler-Toledo International and 12 mentions for Repligen. Repligen's average media sentiment score of 1.41 beat Mettler-Toledo International's score of 1.08 indicating that Repligen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mettler-Toledo International
14 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Repligen
9 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by insiders. Comparatively, 0.6% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mettler-Toledo International has higher revenue and earnings than Repligen. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$4.03B6.69$869.19M$44.4330.27
Repligen$738.26M12.81$48.89M$0.73229.59

Summary

Mettler-Toledo International beats Repligen on 9 of the 17 factors compared between the two stocks.

How does Mettler-Toledo International compare to Bio-Techne?

Mettler-Toledo International (NYSE:MTD) and Bio-Techne (NASDAQ:TECH) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Mettler-Toledo International has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

In the previous week, Mettler-Toledo International had 18 more articles in the media than Bio-Techne. MarketBeat recorded 24 mentions for Mettler-Toledo International and 6 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.35 beat Mettler-Toledo International's score of 1.08 indicating that Bio-Techne is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mettler-Toledo International
14 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bio-Techne
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Mettler-Toledo International has a net margin of 21.91% compared to Bio-Techne's net margin of 14.97%. Bio-Techne's return on equity of 13.23% beat Mettler-Toledo International's return on equity.

Company Net Margins Return on Equity Return on Assets
Mettler-Toledo International21.91% -1,212.14% 25.11%
Bio-Techne 14.97%13.23%10.61%

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 99.0% of Bio-Techne shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 1.3% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Mettler-Toledo International presently has a consensus target price of $1,445.31, suggesting a potential upside of 7.47%. Bio-Techne has a consensus target price of $68.92, suggesting a potential downside of 4.84%. Given Mettler-Toledo International's stronger consensus rating and higher possible upside, analysts plainly believe Mettler-Toledo International is more favorable than Bio-Techne.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mettler-Toledo International
1 Sell rating(s)
8 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.33
Bio-Techne
0 Sell rating(s)
15 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.12

Mettler-Toledo International has higher revenue and earnings than Bio-Techne. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mettler-Toledo International$4.03B6.69$869.19M$44.4330.27
Bio-Techne$1.22B9.35$181.86M$1.1562.98

Summary

Mettler-Toledo International beats Bio-Techne on 9 of the 16 factors compared between the two stocks.

How does Mettler-Toledo International compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Mettler-Toledo International (NYSE:MTD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Agilent Technologies has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market.

Agilent Technologies has higher revenue and earnings than Mettler-Toledo International. Agilent Technologies is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$6.95B6.11$1.30B$5.0829.65
Mettler-Toledo International$4.03B6.69$869.19M$44.4330.27

Mettler-Toledo International has a net margin of 21.91% compared to Agilent Technologies' net margin of 19.53%. Agilent Technologies' return on equity of 24.45% beat Mettler-Toledo International's return on equity.

Company Net Margins Return on Equity Return on Assets
Agilent Technologies19.53% 24.45% 13.09%
Mettler-Toledo International 21.91%-1,212.14%25.11%

Agilent Technologies currently has a consensus target price of $170.33, suggesting a potential upside of 13.10%. Mettler-Toledo International has a consensus target price of $1,445.31, suggesting a potential upside of 7.47%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Agilent Technologies is more favorable than Mettler-Toledo International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agilent Technologies
0 Sell rating(s)
4 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.85
Mettler-Toledo International
1 Sell rating(s)
8 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, Mettler-Toledo International had 9 more articles in the media than Agilent Technologies. MarketBeat recorded 24 mentions for Mettler-Toledo International and 15 mentions for Agilent Technologies. Mettler-Toledo International's average media sentiment score of 1.08 beat Agilent Technologies' score of 0.92 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agilent Technologies
5 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mettler-Toledo International
14 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

95.1% of Mettler-Toledo International shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Mettler-Toledo International beats Agilent Technologies on 9 of the 17 factors compared between the two stocks.

How does Mettler-Toledo International compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Mettler-Toledo International (NYSE:MTD) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Mettler-Toledo International has a net margin of 21.91% compared to Bio-Rad Laboratories' net margin of 8.59%. Bio-Rad Laboratories' return on equity of 3.54% beat Mettler-Toledo International's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories8.59% 3.54% 2.48%
Mettler-Toledo International 21.91%-1,212.14%25.11%

In the previous week, Mettler-Toledo International had 19 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 24 mentions for Mettler-Toledo International and 5 mentions for Bio-Rad Laboratories. Mettler-Toledo International's average media sentiment score of 1.08 beat Bio-Rad Laboratories' score of 0.61 indicating that Mettler-Toledo International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mettler-Toledo International
14 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Mettler-Toledo International has higher revenue and earnings than Bio-Rad Laboratories. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B4.00$759.90M$8.2546.82
Mettler-Toledo International$4.03B6.69$869.19M$44.4330.27

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 0.7% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bio-Rad Laboratories has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Mettler-Toledo International has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Bio-Rad Laboratories currently has a consensus target price of $343.33, suggesting a potential downside of 11.11%. Mettler-Toledo International has a consensus target price of $1,445.31, suggesting a potential upside of 7.47%. Given Mettler-Toledo International's stronger consensus rating and higher probable upside, analysts clearly believe Mettler-Toledo International is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Mettler-Toledo International
1 Sell rating(s)
8 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Mettler-Toledo International beats Bio-Rad Laboratories on 13 of the 16 factors compared between the two stocks.

Get Mettler-Toledo International News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MTD vs. The Competition

Export
MetricMettler-Toledo InternationalLife Sciences Tools & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$26.95B$9.93B$7.21B$23.59B
Dividend YieldN/A1.47%2.54%3.73%
P/E Ratio30.2764.78273.8329.33
Price / Sales6.69111.36622.2020.96
Price / Cash27.1026.8528.9219.95
Price / Book-1,159.375.3711.014.83
Net Income$869.19M$56.67B$3.49B$1.07B
7 Day Performance-4.35%-0.68%1.64%0.43%
1 Month Performance-5.90%1.60%4.42%-0.78%
1 Year Performance3.08%24.28%24.20%12.82%

Mettler-Toledo International Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTD
Mettler-Toledo International
3.9361 of 5 stars		$1,344.87
0.0%		$1,445.31
+7.5%		+3.1%$26.95B$4.03B30.2718,100
BRKR
Bruker
2.6711 of 5 stars		$58.01
+1.6%		$56.64
-2.4%		+89.8%$8.70B$3.50BN/A11,085
RGEN
Repligen
3.2598 of 5 stars		$180.98
+2.7%		$166.43
-8.0%		+34.6%$9.95B$738.26M247.922,000
TECH
Bio-Techne
3.457 of 5 stars		$72.31
-0.1%		$68.92
-4.7%		+33.1%$11.35B$1.22B62.883,000
A
Agilent Technologies
4.8475 of 5 stars		$153.79
0.0%		$170.33
+10.8%		+17.0%$43.45B$6.95B30.2718,100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:MTD) was last updated on 9/7/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel